Therefore, we aimed to test whether mutations in KEAP1, identified in our previous study, accelerate the development of lung cancer, and whether a NRF2 inhibitor can be used as a targeted therapeutic drug in patients with lung cancer carrying KEAP1/NRF2 mutations. The gene discussed is NFE2L2; the disease is lung cancer.